Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $1.92 Million - $2.18 Million
40,000 New
40,000 $2.17 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $358,752 - $428,090
-7,400 Reduced 7.97%
85,500 $4.39 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $428,386 - $479,002
7,400 Added 8.65%
92,900 $5.39 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $5.45 Million - $6.05 Million
85,500 New
85,500 $5.47 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $38.4 Million - $45.5 Million
560,900 Added 50.82%
1,664,600 $115 Million
Q3 2022

Nov 15, 2022

BUY
$0.13 - $76.84 $90,207 - $53.3 Million
693,900 Added 169.33%
1,103,700 $75.5 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $29.5 Million - $32.5 Million
405,900 Added 10407.69%
409,800 $30 Million
Q1 2022

May 18, 2022

SELL
$61.48 - $73.72 $32 Million - $38.3 Million
-520,000 Reduced 99.26%
3,900 $275,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $6.26 Million - $7.3 Million
116,800 Added 28.69%
523,900 $31.6 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $2.64 Million - $3.09 Million
44,600 Added 12.3%
407,100 $23.7 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $532,426 - $579,812
8,600 Added 2.43%
362,500 $23.4 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $17.6 Million - $19.7 Million
295,900 Added 510.17%
353,900 $21.6 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $792,281 - $1.03 Million
-16,100 Reduced 21.73%
58,000 $3.58 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $104 Million - $115 Million
-2,333,600 Reduced 96.92%
74,100 $3.41 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $109 Million - $130 Million
2,407,700 New
2,407,700 $114 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Nomura Holdings Inc Portfolio

Follow Nomura Holdings Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.